The Cigna Group logo

The Cigna Group (CI)

Market Closed
5 Dec, 20:00
NYSE NYSE
$
265. 44
-2.98
-1.11%
After Hours
$
267. 00
+1.56 +0.59%
74.35B Market Cap
16.39 P/E Ratio
5.6% Div Yield
867,447 Volume
24.83 Eps
$ 268.42
Previous Close
Day Range
263.87 269.08
Year Range
239.51 350
Want to track CI and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 54 days
CVS, Cigna unveil Medicare Advantage plans for 2025

CVS, Cigna unveil Medicare Advantage plans for 2025

CVS Health and Cigna on Tuesday released details on their government-backed health insurance plans for next year for people aged 65 and above, saying some members would pay $0 premium monthly for prescription drugs.

Reuters | 1 year ago
Here's Why Cigna (CI) is a Strong Value Stock

Here's Why Cigna (CI) is a Strong Value Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks | 1 year ago
Cigna: This Dividend Grower Could Be Worth Buying Now

Cigna: This Dividend Grower Could Be Worth Buying Now

The managed care company's total revenue and non-GAAP EPS climbed higher in the second quarter. Cigna's dividend is comfortably covered by non-GAAP EPS and free cash flow. Shares of the stock appear to be priced at a 17% discount to fair value.

Seekingalpha | 1 year ago
Are CVS Health, Cigna, and UnitedHealth Group Stocks Bad News Buys With the FTC's PBM Crackdown?

Are CVS Health, Cigna, and UnitedHealth Group Stocks Bad News Buys With the FTC's PBM Crackdown?

The FTC is suing CVS Health, Cigna, and UnitedHealth Group because of alleged uncompetitive PBM practices. Their PBM units are major revenue sources for all three healthcare companies.

Fool | 1 year ago
Pharmacy benefit managers respond to FTC's lawsuit over insulin drug prices

Pharmacy benefit managers respond to FTC's lawsuit over insulin drug prices

CNBC's Eamon Javers joins 'The Exchange' to report the latest on the FTC's lawsuit against drug middlemen for allegedly inflating insulin prices.

Youtube | 1 year ago
Explainer: Why are US pharmacy benefit managers under fire?

Explainer: Why are US pharmacy benefit managers under fire?

The U.S. Federal Trade Commission said on Friday it was suing the country's three largest pharmacy benefit managers, accusing them of abusing their power and rigging the pharmaceutical supply chain to artificially inflate the cost of insulin.

Reuters | 1 year ago
Cigna: Growth From Specialty Pharmacy And Care; Initiate With 'Buy'

Cigna: Growth From Specialty Pharmacy And Care; Initiate With 'Buy'

I am initiating a 'Buy' rating for Cigna with a one-year target price of $450 per share, driven by strong Specialty and Cigna Healthcare growth. Cigna's Specialty Pharmacy and Care Market, accounting for 30% of revenue, is poised for above-market growth due to its leadership in the chronic market and biosimilar offerings. Cigna Healthcare's divestiture of low-margin Medicare businesses will allow focus on employer-sponsored plans, targeting small and mid-size enterprises, contributing to 7% organic revenue growth.

Seekingalpha | 1 year ago
Cigna Launches E-Treatment Service for Convenient Patient Access

Cigna Launches E-Treatment Service for Convenient Patient Access

As the telehealth sector is projected to reach $450 billion by 2032, Cigna Healthcare recently launched an “E-Treatment” option via MDLIVE, offering customers access to urgent care from board-certified doctors without the need for direct phone or video consultations.

Pymnts | 1 year ago
Cigna's PBM Express Scripts sues the FTC, seeking retraction of drug-cost report

Cigna's PBM Express Scripts sues the FTC, seeking retraction of drug-cost report

Cigna Group's pharmacy benefit manager Express Scripts on Tuesday sued the U.S. Federal Trade Commission, alleging that the agency's July report on the PBM industry was biased and defamatory and asking the court to order the FTC to withdraw the report.

Marketwatch | 1 year ago
Cigna Demands FTC Retraction in Escalating Drug-Price Fight

Cigna Demands FTC Retraction in Escalating Drug-Price Fight

One of the country's biggest pharmacy-benefit managers, Cigna Group's CI 0.58%increase; green up pointing triangle Express Scripts, sued the Federal Trade Commission, demanding a retraction of a recent report critical of the companies that negotiate drug spending.

Wsj | 1 year ago
Cigna's Health Benefits Unit Launches a New E-Treatment Option

Cigna's Health Benefits Unit Launches a New E-Treatment Option

CI's new launch, a new E-Treatment option, is expected to improve patient satisfaction and operational efficiency.

Zacks | 1 year ago
Cigna Stock Gains 26% in a Year: What Lies Ahead for Investors?

Cigna Stock Gains 26% in a Year: What Lies Ahead for Investors?

CI benefits from improved premiums resulting from an extensive customer base. Buyouts and adequate operating cash flows are other tailwinds.

Zacks | 1 year ago
Loading...
Load More